Symbols

MIST

Milestone·NASDAQ

--(--)

MIST fundamentals

MIST Q4 2025 Earnings

Milestone (MIST) released its earnings on Mar 20, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.16 (YoY +15.79%), beat estimates.

Revenue / YoY

EPS / YoY

-0.16

+15.79%

Report date

Mar 20, 2026

MIST Earnings Call Summary for Q4,2025

FDA Approval Milestone: CARDAMYST launched in January 2026, achieving 150 prescriptions within the first month, driven by new patient starts.
Financial Strength: $200 million cash runway supports operations into late 2027, with $75 million from royalty sale and $10.9 million from ATM.
Commercial Momentum: 60 sales reps targeting 10,000 prescribers, with early prescriber engagement across cardiology, electrophysiology, and APPs.
Reimbursement Focus: 50-70% of scripts face prior auth delays; patient assistance programs and direct support are mitigating barriers.
Supply Assurance: Manufacturing capacity meets demand, with routine production cadence in place.

Earnings

EPS

Revenue

Revenue & Expenses

MIST has released its 2025 Q4 earnings report, with revenue of 1.55M, reflecting a YoY change of NaN%, and net profit of -17.41M, showing a YoY change of -40.82%. The Sankey diagram below clearly presents MIST's revenue sources and cost distribution.

Key Indicators

Milestone (MIST) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Milestone (MIST)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Milestone (MIST)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Milestone (MIST)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown